Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Syndax Announces Completion of Enrollment in...
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Syndax Pharmaceuticals Inc (SNDX), where a total of 7,142 contracts have traded so far...
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of...
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer Syndax Announces Appointment of Steven Closter as Chief Commercial Officer PR Newswire WALTHAM, Mass., March 18, 2024 Steven...